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dergoing transcatheter aortic valve replacement, elevated neutrophil
to lymphocyte ratio was associated with increased mortality at 30
days. This effect was independent of previously established risk
predictors in these patients. More large scale randomized studies are
needed to further evaluate these results.
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BACKGROUND Transcatheter aortic valve-in-valve (ViV) implantation
inside failed bioprostheses is an alternative approach to repeat open
heart surgery for those with failed bioprosthetic valves. However,
stentless surgical valves lack ﬂuoroscopic markers and provide
distinctive challenges. Our objective was to compare clinical out-
comes following aortic ViV procedures in stentless vs. stented bio-
prostheses, using a large global registry.
METHODS A total of 1,104 aortic ViV procedures from the ViV Inter-
national Data (VIVID) registry were investigated (903 stented bio-
prostheses, 201 stentless).
RESULTS Patients with stentless bioprostheses were younger and had
similar STS risk of mortality scores when compared to their stentedcounterparts (74.7 12.4 vs. 78.68 8.3, p< 0.001; 9.8 8.4 vs. 10.5 9.3,
p¼0.41, respectively). Stentlessbioprostheseshada longermedian time to
failure and failed predominantly with regurgitation (12 vs. 9 years, p <
0.001; 57.6%vs. 25.6% regurgitation, p<0.001, respectively). The effective
oriﬁce area was larger in stentless valves than in stented ones (valve area
1.2  1.5 vs. 0.94  0.6 cm2, p ¼ 0.02, respectively), with smaller mean
gradients as well (27.1 vs. 37.63 mmHg, p < 0.001, respectively). Stentless
bioprostheses were more commonly treated with self-expandable devices
(66.8% vs. 54.5% of stented, p < 0.001) and transesophageal echocardi-
ography was more commonly utilized in these procedures (73.1% vs.
56.4%, p < 0.001). Device malposition was more common in stentless and
Mosaic surgical valves than in stentednon-Mosaicones (12.3%vs. 12.4%vs.
5.1%, p < 0.001, respectively). There was a greater need for second trans-
catheter heart valve device in stentless valves as well (8.5% vs. 3.6%, p ¼
0.002). Coronary obstruction was more common in stentless valves (5.8%
vs. 1%,p<0.001). Final aortic valve areawasgreater in stentlessprostheses
(1.75  0.4 vs. 1.41  0.6 cm2, p < 0.001) and post-procedure mean gradi-
entswere also lower in this group (11.7 7 vs. 17.2 9.6mmHg, p< 0.001).
There was a trend towards higher 30-day mortality in stentless valves
(8.4%vs. 5%, p¼ 0.07). However, 1-yearmortalitywas similar between the
groups (14% stentless vs. 16.6% stented, p ¼ 0.59).
CONCLUSIONS Aortic ViV procedures inside stentless bioprostheses
are challenging and associated with more device malposition, coro-
nary obstruction and a trend towards increased short-term mortality.
However, stentless ViV procedures offers improved hemodynamics
with similar survival rates at one year.
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BACKGROUND The latest generation of the balloon-expandable
Edwards SAPIEN device, the SAPIEN 3, has shown very positive re-
sults in recently published studies. Most notably, it demonstrated a
low rate in paravalvular regurgitation, a low rate in vascular access
site complications, a low stroke rate and a very low mortality rate.
These clinical outcomes are mainly due to signiﬁcant design im-
provements: downsizing of the delivery system (Edwards Commander
delivery system) with sizes of 14F (23 mm and 26 mm device) and 16F
(29mm device) and a paravalvular sealing cuff to reduce the amount
of residual paravalvular regurgitation. According to these changes,
new sizing recommendations were developed for the SAPIEN 3 device,
which even allows slight undersizing.
METHODS To analyze the percentage of patientswho couldhave received
a SAPIEN 3 device in a transfemoral TAVR patient cohort. We retrospec-
tively reviewed CT-scans of 201 TAVR patients implanted between
February 2014 (when the SAPIEN 3 was introduced at our hospital) and
April 2015 and compared the suitability for the SAPIEN 3 and SAPIEN XT
respectively, based on access vessel and/or the 3D annulus diameter.
RESULTS With respect to the new sizing guidelines for the SAPIEN 3,
196 patients (98%) of the 201 patients analyzed would have been suit-
able for an implantation with the new SAPIEN 3 device. In contrary, the
SAPIEN XT device could have been implanted in signiﬁcantly less pa-
tients (80%). The SAPIEN 3 device was ﬁnally implanted in 102 patients
(52%). The short-term outcome of this cohort showed excellent results.
Paravalvular regurgitation was virtually absent with the vast majority
having none or trace postinterventional aortic regurgitation on echo-
cardiography (90.7%). None of the patients had more than mild para-
valvular regurgitation. Major vascular access site complications or
major bleeding according to the VARC II criteria were not observed in
our cohort. Minor vascular complications and minor bleeding occurred
in 6.8 % and 3.9 % respectively. If vascular complication occurred, they
were related to closure device failure with subsequent stent graft im-
plantation. Thirty-day outcome showed a very low major stroke rate
(1.9%) and a low mortality rate (2.9%). However, we observed a 20.6%
permanent pacemaker rate in our SAPIEN 3 cohort.
